Target Price | $31.62 |
Price | $13.90 |
Potential |
127.48%
register free of charge
|
Number of Estimates | 14 |
14 Analysts have issued a price target EyePoint Pharmaceuticals, Inc. 2026 .
The average EyePoint Pharmaceuticals, Inc. target price is $31.62.
This is
127.48%
register free of charge
$71.40
413.67%
register free of charge
$23.23
67.12%
register free of charge
|
|
A rating was issued by 19 analysts: 18 Analysts recommend EyePoint Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the EyePoint Pharmaceuticals, Inc. stock has an average upside potential 2026 of
127.48%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 43.27 | 37.37 |
5.98% | 13.63% | |
EBITDA Margin | -333.51% | -636.58% |
104.45% | 90.87% | |
Net Margin | -302.45% | -573.64% |
96.59% | 89.66% |
15 Analysts have issued a sales forecast EyePoint Pharmaceuticals, Inc. 2025 . The average EyePoint Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an EyePoint Pharmaceuticals, Inc. EBITDA forecast 2025. The average EyePoint Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
15 EyePoint Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average EyePoint Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -2.32 | -3.11 |
27.47% | 34.05% | |
P/E | negative | |
EV/Sales | 18.79 |
15 Analysts have issued a EyePoint Pharmaceuticals, Inc. forecast for earnings per share. The average EyePoint Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
EyePoint Pharmaceuticals, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
Chardan Capital |
Locked
➜
Locked
|
Locked | Aug 07 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 06 2025 |
RBC Capital |
Locked
➜
Locked
|
Locked | Jun 17 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 29 2025 |
Mizuho |
Locked
➜
Locked
|
Locked | May 16 2025 |
Chardan Capital |
Locked
➜
Locked
|
Locked | May 08 2025 |
Chardan Capital |
Locked
➜
Locked
|
Locked | Mar 06 2025 |
Analyst Rating | Date |
---|---|
Locked
Chardan Capital:
Locked
➜
Locked
|
Aug 07 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 06 2025 |
Locked
RBC Capital:
Locked
➜
Locked
|
Jun 17 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 29 2025 |
Locked
Mizuho:
Locked
➜
Locked
|
May 16 2025 |
Locked
Chardan Capital:
Locked
➜
Locked
|
May 08 2025 |
Locked
Chardan Capital:
Locked
➜
Locked
|
Mar 06 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.